Molnupiravir linked to COVID mutations Researchers found the widely used antiviral could be driving new SARS-CoV-2 variants, but there is no evidence these pose any additional threat.
New antiviral may offer ‘less cumbersome’ COVID treatment option The Chinese-developed oral antiviral reportedly achieves similar outcomes to Paxlovid, but with fewer side effects and drug–drug interactions.
GPs urged to not dismiss molnupiravir entirely While guidelines say the drug should be only prescribed as a ‘last resort’, there are concerns this could deter GPs from prescribing the treatment altogether.
Molnupiravir to be used only as a last resort: Taskforce Advice has changed for the country’s most prescribed COVID-19 oral antiviral, although access via the PBS will remain in place.
Doubts over impact of key antiviral treatment A large UK study suggests molnupiravir has no effect on hospitalisations and deaths but reduces the overall recovery time from COVID-19.
Push to allow pharmacist prescribing of antivirals flipped on its head A ‘more sensible approach’ would see the lifesaving medications added to the Doctor’s Bag, a prominent GP has said.
Could anticipatory deprescribing allow better COVID treatment? Despite being more effective according to some studies, Paxlovid prescriptions lag Lagevrio, with drug–drug interactions likely to play a part.
Trial shows muted impact of Paxlovid on healthier patients New data confirms limited efficacy for those at ‘standard risk’, with more positive results for higher risk cohorts.
First real-world studies on COVID-19 oral antivirals emerge Pre-print studies are beginning to flesh out understanding of efficacy, suggesting Paxlovid may have a greater impact – particularly on at-risk older people.
Health officials flag increased use of antivirals as COVID becomes endemic The new oral treatments are likely to play a more central role in limiting the impact of COVID-19, but health authorities are still assessing how that will take shape.